再生医療市場：タイプ別、用途別-2025-2030年の世界予測

再生医療市場は、2023年に230億2,000万米ドルと評価され、2024年には283億5,000万米ドルに達すると予測され、CAGR 23.76％で成長し、2030年には1,024億米ドルになると予測されています。

再生医療は、幹細胞治療、組織工学、遺伝子編集などの技術を用いて、損傷した組織や臓器を修復、置換、再生することに焦点を当てた変革的ヘルスケア分野です。その必要性は、慢性疾患の増加、人口の高齢化、従来の医療療法の限界から生じています。用途は整形外科、皮膚科、心臓病学、神経学など多岐にわたる。最終用途分野は、病院や診療所から研究機関やバイオテクノロジー企業まで幅広く、市場の可能性の広さを浮き彫りにしています。市場の成長は、バイオテクノロジーや材料科学の進歩、政府や民間からの資金提供の増加、再生治療に対する意識の高まりなど、いくつかの要因に影響されています。潜在的なビジネスチャンスは、未開拓の新興市場、継続的な研究開発、主要企業間の戦略的提携にあります。

しかし、治療費の高騰、厳しい規制の枠組み、幹細胞使用に伴う倫理的懸念、生産規模の拡大における技術的ハードルなど、この市場における限界や課題も存在します。また、治療法の標準化や治療効果の長期化といった課題もあります。事業の成長を促進するためには、費用対効果の高いバイオ加工技術の開発、個別化医療のためのAIと機械学習の活用、組織工学のための足場材料の強化などに技術革新の機会が存在します。さらに、非侵襲的な再生治療に焦点を当て、治療モニタリングのための信頼性の高いバイオマーカーを創出することも、有利な道を示す可能性があります。

競合情勢は急速に進化しており、絶え間ない技術革新と戦略的先見性が必要とされます。企業は学際的なコラボレーションやパートナーシップに投資し、アイデアや技術を相互に伝播させることで、革新曲線の先を行くべきです。この市場は、技術革新とアンメット・ニーズへの対応という2つの力によって、大きく拡大する態勢を整えています。こうした複雑な力学を賢く操ることができれば、市場で確固たる地位を築き、世界のヘルスケアの発展に大きく貢献することができると思われます。

市場力学：急速に進化する再生医療市場の主要市場インサイトを公開

再生医療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 幹細胞技術、遺伝子治療、組織工学の採用拡大
  • 政府による研究投資の増加
  • 製品承認と民間企業による研究開発活動の活発化
• 市場抑制要因
  • 幹細胞および再生医療に関する高コストと規制の問題
• 市場機会
  • 再生医療生物製剤の技術的進歩
  • 臓器移植や骨移植の需要の高まり
• 市場の課題
  • 研究開発における胚性幹細胞の使用に関する倫理的問題

ポーターのファイブフォース：再生医療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：再生医療市場における外部からの影響の把握

外部マクロ環境要因は、再生医療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析再生医療市場における競合情勢の把握

再生医療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス再生医療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、再生医療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨再生医療市場における成功への道筋を描く

再生医療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 幹細胞技術、遺伝子治療、組織工学の導入の増加
    • 再生医療調査への政府投資の増加
    • 民間企業による研究開発活動の増加と相まって製品承認
  • 抑制要因
    • 幹細胞に関する高コストと規制の問題と再生医療
  • 機会
    • 再生医療生物製剤における技術的進歩
    • 臓器移植と骨移植の需要増加
  • 課題
    • 研究開発における胚性幹細胞の使用に関する倫理的問題
• 市場セグメンテーション分析
  • タイプ：個別化治療における細胞ベースの免疫療法および細胞治療製品の重要な応用
  • 応用：心血管疾患における再生医療の重要性の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 再生医療市場：タイプ別

• 細胞ベースの免疫療法および細胞治療製品
  • 同種製品
  • 自家製品
• 遺伝子治療製品
• 低分子・生物製剤
• 組織工学製品

第7章 再生医療市場：用途別

• 心臓血管
• 糖尿病
• 筋骨格障害
• 眼疾患
• 腫瘍学
• 創傷ケア

第8章 南北アメリカの再生医療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の再生医療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの再生医療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 4DMTがFDAからウェット AMDの硝子体内治療用遺伝子医薬品 4D-150の先進治療指定を取得
  • シスメックスとJCRファーマの合弁会社アライドセルが再生医療製品の早期社会実装を推進する新たなパイプラインを獲得
  • マウントサイナイが再生医療研究所を設立
• 戦略分析と提言

企業一覧

• 4D Molecular Therapeutics, Inc.
• Allergan PLC
• Amgen Inc.
• Astellas Pharma Inc.
• Athersys, Inc.
• Bayer AG
• CMIC HOLDINGS Co., LTD.
• Editas Medicine, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Gilead Sciences, Inc.
• Integra LifeSciences Holdings Corporation
• JCR Pharmaceuticals Co., Ltd.
• Medtronic PLC
• Mimedx Group
• Novartis AG
• Organogenesis Inc.
• Osiris Therapeutics, Inc. by Smith & Nephew PLC
• REPROCELL Inc.
• SanBio Company Limited
• Sartorius AG
• Sumitomo Pharma Co., Ltd.
• Sysmex Corporation
• Takeda Pharmaceutical Co. Ltd.
• Tenaya Therapeutics, Inc.
• Vericel Corporation
• Wright Medical Group N.V.
• Zimmer Biomet Holdings Inc.

LIST OF FIGURES

• FIGURE 1. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
• FIGURE 2. REGENERATIVE MEDICINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. REGENERATIVE MEDICINE MARKET DYNAMICS
• TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SMALL MOLECULE & BIOLOGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE-ENGINEERED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY WOUND CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 51. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 54. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 106. ITALY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 118. POLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 121. QATAR REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 150. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

The Regenerative Medicine Market was valued at USD 23.02 billion in 2023, expected to reach USD 28.35 billion in 2024, and is projected to grow at a CAGR of 23.76%, to USD 102.40 billion by 2030.

Regenerative medicine is a transformative healthcare arena focused on repairing, replacing, or regenerating damaged tissues and organs using techniques like stem cell therapy, tissue engineering, and gene editing. Its necessity arises from the increasing prevalence of chronic diseases, aging populations, and the limitations of conventional medical therapies. Applications are vast, spanning orthopedics, dermatology, cardiology, and neurology, among others. End-use sectors range from hospitals and clinics to research institutions and biotech companies, highlighting its broad market potential. The market growth is influenced by several factors: advancements in biotechnology and material science, an increase in government and private funding, and rising awareness about regenerative treatments. Potential opportunities lie in untapped emerging markets, continual R&D, and strategic collaborations among key industry players.

However, limitations and challenges in this market include high costs of treatment, stringent regulatory frameworks, ethical concerns associated with stem cell use, and technical hurdles in scaling production. The sector also faces challenges related to the standardization of therapies and the long-time horizon for treatment efficacy. To foster business growth, innovation opportunities exist in developing cost-effective bioprocessing techniques, leveraging AI and machine learning for personalized medicine, and enhancing scaffolding materials for tissue engineering. Additionally, focusing on non-invasive regenerative therapies and creating reliable biomarkers for treatment monitoring could present lucrative avenues.

The regenerative medicine market is characterized by intense research and a rapidly evolving competitive landscape, necessitating constant technological advancements and strategic foresight. Companies should invest in interdisciplinary collaborations and partnerships to cross-pollinate ideas and technologies, thereby staying ahead in the innovation curve. This market is poised for significant expansion, driven by the dual forces of innovation and the unmet clinical needs it seeks to address. Those navigating these intricate dynamics wisely are likely to achieve robust market positions and contribute meaningfully to the advancement of global healthcare.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Regenerative Medicine Market

The Regenerative Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
  • Rising government investments in regenerative medicine research
  • Product approval coupled with increasing R&D activities by private players
• Market Restraints
  • High cost and regulatory issues pertaining to stem cell and regenerative medicine
• Market Opportunities
  • Technological advancements in regenerative medicine biologics
  • Growing demand for organ transplantation and bone grafting
• Market Challenges
  • Ethical issues related to the use of embryonic stem cells in R&D

Porter's Five Forces: A Strategic Tool for Navigating the Regenerative Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Regenerative Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Regenerative Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Regenerative Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Regenerative Medicine Market

A detailed market share analysis in the Regenerative Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Regenerative Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Regenerative Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Regenerative Medicine Market

A strategic analysis of the Regenerative Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Allergan PLC, Amgen Inc., Astellas Pharma Inc., Athersys, Inc., Bayer AG, CMIC HOLDINGS Co., LTD., Editas Medicine, Inc., FUJIFILM Cellular Dynamics, Inc., Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., Medtronic PLC, Mimedx Group, Novartis AG, Organogenesis Inc., Osiris Therapeutics, Inc. by Smith & Nephew PLC, REPROCELL Inc., SanBio Company Limited, Sartorius AG, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Co. Ltd., Tenaya Therapeutics, Inc., Vericel Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings Inc..

Market Segmentation & Coverage

This research report categorizes the Regenerative Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule & Biologic, and Tissue-Engineered Products. The Cell-Based Immunotherapy & Cell Therapy Products is further studied across Allogeneic Products and Autologous Products.
• Based on Application, market is studied across Cardiovascular, Diabetes, Musculoskeletal Disorders, Ocular Disorders, Oncology, and Wound Care.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing adoption of stem cell technologies, gene therapies, and tissue engineering
    • 5.1.1.2. Rising government investments in regenerative medicine research
    • 5.1.1.3. Product approval coupled with increasing R&D activities by private players
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and regulatory issues pertaining to stem cell and regenerative medicine
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in regenerative medicine biologics
    • 5.1.3.2. Growing demand for organ transplantation and bone grafting
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical issues related to the use of embryonic stem cells in R&D
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Significant applications of cell-based immunotherapies and cell therapy products in personalized treatment
  • 5.2.2. Application: Growing significance of regenerative medicines for cardiovascular diseases
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Regenerative Medicine Market, by Type

• 6.1. Introduction
• 6.2. Cell-Based Immunotherapy & Cell Therapy Products
  • 6.2.1. Allogeneic Products
  • 6.2.2. Autologous Products
• 6.3. Gene Therapy Products
• 6.4. Small Molecule & Biologic
• 6.5. Tissue-Engineered Products

7. Regenerative Medicine Market, by Application

• 7.1. Introduction
• 7.2. Cardiovascular
• 7.3. Diabetes
• 7.4. Musculoskeletal Disorders
• 7.5. Ocular Disorders
• 7.6. Oncology
• 7.7. Wound Care

8. Americas Regenerative Medicine Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Regenerative Medicine Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Regenerative Medicine Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. 4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD
  • 11.3.2. AlliedCel, a Joint Venture Between Sysmex and JCR Pharmaceuticals, Has Acquired a New Pipeline to Promote the Early Social Implementation of Regenerative Medicine Products
  • 11.3.3. Mount Sinai Launches Institute for Regenerative Medicine
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Molecular Therapeutics, Inc.
• 2. Allergan PLC
• 3. Amgen Inc.
• 4. Astellas Pharma Inc.
• 5. Athersys, Inc.
• 6. Bayer AG
• 7. CMIC HOLDINGS Co., LTD.
• 8. Editas Medicine, Inc.
• 9. FUJIFILM Cellular Dynamics, Inc.
• 10. Gilead Sciences, Inc.
• 11. Integra LifeSciences Holdings Corporation
• 12. JCR Pharmaceuticals Co., Ltd.
• 13. Medtronic PLC
• 14. Mimedx Group
• 15. Novartis AG
• 16. Organogenesis Inc.
• 17. Osiris Therapeutics, Inc. by Smith & Nephew PLC
• 18. REPROCELL Inc.
• 19. SanBio Company Limited
• 20. Sartorius AG
• 21. Sumitomo Pharma Co., Ltd.
• 22. Sysmex Corporation
• 23. Takeda Pharmaceutical Co. Ltd.
• 24. Tenaya Therapeutics, Inc.
• 25. Vericel Corporation
• 26. Wright Medical Group N.V.
• 27. Zimmer Biomet Holdings Inc.